Premium
Does the oral steroid treatment of patients with nasal polyposis cause osteopenia or osteoporosis?
Author(s) -
SahlstrandJohnson Pernilla,
Holmström Mats,
Ehnhage Anders
Publication year - 2019
Publication title -
clinical otolaryngology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.914
H-Index - 68
eISSN - 1749-4486
pISSN - 1749-4478
DOI - 10.1111/coa.13431
Subject(s) - medicine , osteopenia , osteoporosis , bone mineral , prednisone , bone density , physical therapy
Objectives We aimed to investigate the bone mineral density (BMD) in a group of Swedish patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) with or without asthma, as well as to evaluate whether the treatment of this patient group is in accordance with the EPOS recommendations. Design, settings and participants Adult patients with a diagnosis of CRSwNP, and a history of at least two courses of oral corticosteroids (OCS) during the last year, were consecutively included in this study at five centres. Main outcome measures The BMD of the patients was measured by Dual‐energy X‐ray absorptiometry (DXA), which is the only technology for classifying BMD according to the criteria established by WHO. Results A total of 51 patients, with an average number of 7 years with OCS treatment, were enrolled. During the last 12 months, the mean number of OCS courses was 2.76, and the total mean intake was 891 mg of Prednisone equivalents. According to the T‐scores, 17 patients were measured to have ≤−1 SD T‐score lumbar spine, which is considered to be osteopenia, and five patients had <−2.5 SD T‐score, considered as osteoporosis. However, when taking age and gender into account and analysing the Z‐scores, only 2 patients had a reduced density of the spine and none in the hip, which is no difference compared to a matched Swedish population. Conclusions This prospective study shows that 2‐3 moderate courses of OCS annually may be used without high risk of causing osteopenia/osteoporosis in patients with CRSwNP.